TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 121 filers reported holding TCR2 THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.04 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $61,000 | -52.0% | 22,200 | -18.7% | 0.00% | – |
| Q4 2021 | $127,000 | -45.3% | 27,300 | 0.0% | 0.00% | – |
| Q3 2021 | $232,000 | -48.2% | 27,300 | 0.0% | 0.00% | – |
| Q2 2021 | $448,000 | -2.0% | 27,300 | +31.9% | 0.00% | – |
| Q1 2021 | $457,000 | -38.7% | 20,700 | -14.1% | 0.00% | – |
| Q4 2020 | $745,000 | +232.6% | 24,100 | +119.1% | 0.00% | – |
| Q3 2020 | $224,000 | -9.3% | 11,000 | -31.7% | 0.00% | – |
| Q2 2020 | $247,000 | – | 16,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
| Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
| Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
| Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
| PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
| Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
| MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
| Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |